Operator

Good morning, and welcome to MiNK Therapeutics First Quarter 2026 Conference Call and Webcast. [Operator Instructions] Please note, this event is being recorded. And I would now like to turn the conference over to Stefanie Perna-Nacar from MiNK Investor Relations. Stefanie, please go ahead.

Stefanie Perna-Nacar

Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and commercial plans, time lines for data releases and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings, also available on our website for a detailed description of these risks.

Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics; Dr. Terese Hammond, Head of Development; and Melissa Orilall, Principal Financial Officer. I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter. Jennifer?

Jennifer Buell
Co-Founder, President, CEO & Director

Thank you, Stefanie. Good morning, everyone, and thank you for joining us today. Over the past several weeks, we've presented data at 4 major international scientific meetings, beginning with findings in pulmonary fibrosis with the Keystone Symposium in February, followed by a presentation of our Phase II clinical data in refractory gastric cancer at AACR in April. And most recently, in fact, just earlier this week, we presented